EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical TimelinesGlobeNewsWire • 01/05/23
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/02/22
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 11/02/22
EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022GlobeNewsWire • 10/26/22
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic RetinopathyGlobeNewsWire • 09/29/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 09/01/22
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 09/01/22
Berman Tabacco Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) for Potential Securities Law ViolationsNewsfile Corp • 08/31/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of InvestorsBusiness Wire • 08/31/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 08/31/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of InvestorsBusiness Wire • 08/31/22
EyePoint Pharmaceuticals Shareholder News: Johnson Fistel Encourages EYPT Shareholders with Losses to Contact the Firm Regarding InvestigationNewsfile Corp • 08/31/22
The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of InvestorsBusiness Wire • 08/30/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 08/30/22
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/22
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 08/03/22
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDPRNewsWire • 08/01/22
EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022GlobeNewsWire • 07/27/22